Addressing the Growing Challenge of Access to Eye Care for Retinal Diseases
The inherited retinal disease (IRD) community often faces unique hurdles in accessing specialized care and treatments. While the recent Ophthalmology Times Europe article, "Access Challenges in Retinal Vascular Diseases," focuses on vascular conditions, its insights into broader systemic issues within ophthalmology are highly relevant to IRD patients and their families. Understanding these challenges in the wider retinal disease landscape can shed light on potential obstacles and advocacy opportunities for those living with IRDs.
The article highlights significant concerns regarding the future availability of eye care professionals. Ophthalmology is projected to face one of the steepest physician shortages among all medical subspecialties by 2038, with a predicted 28% deficit. This shortage is attributed, in part, to the number of ophthalmology residents not keeping pace with the growing and aging global population.
These access issues are particularly pressing in Europe, where populations are experiencing increasing rates of retinal diseases due to demographic changes and an aging population. For instance, more than one million Europeans aged 55 and older are affected by Retinal Vein Occlusion (RVO), requiring treatments like intravitreal injections. Similarly, the number of patients affected by Age-related Macular Degeneration (AMD) in the EU is expected to rise by almost 25% by 2050. Diabetic eye disease also impacts nearly 4 million individuals in the EU, with almost one million requiring treatment. These conditions, along with others, contribute to an increasing prevalence of visual impairment and blindness.
For patients and families in the IRD community, these findings underscore a critical concern. A general shortage of ophthalmologists and challenges in healthcare service provision for common retinal diseases could inadvertently impact access to the highly specialized care often required for IRDs. Delays in accessing diagnosis, monitoring, and novel therapies—which are often complex and require expert administration—could become more pronounced if the overall capacity of the eye care system is strained. The article notes that patients with neovascular AMD (nAMD) already experience delays in treatment access, low treatment frequency, and suboptimal monitoring, leading to worse outcomes than seen in clinical studies. This suggests a systemic issue that could affect other complex retinal conditions.
Addressing these challenges will require concerted efforts to increase the number of trained ophthalmologists and improve healthcare infrastructure. Continued investment in education, faculty development, and robust training standards will be essential to ensure that all patients with retinal diseases, including those with IRDs, receive timely and effective care in the years to come.